全文获取类型
收费全文 | 8377篇 |
免费 | 660篇 |
国内免费 | 23篇 |
专业分类
耳鼻咽喉 | 77篇 |
儿科学 | 409篇 |
妇产科学 | 191篇 |
基础医学 | 1026篇 |
口腔科学 | 250篇 |
临床医学 | 1123篇 |
内科学 | 1457篇 |
皮肤病学 | 117篇 |
神经病学 | 717篇 |
特种医学 | 290篇 |
外国民族医学 | 3篇 |
外科学 | 826篇 |
综合类 | 173篇 |
一般理论 | 13篇 |
预防医学 | 1180篇 |
眼科学 | 90篇 |
药学 | 543篇 |
1篇 | |
中国医学 | 16篇 |
肿瘤学 | 558篇 |
出版年
2023年 | 65篇 |
2022年 | 106篇 |
2021年 | 283篇 |
2020年 | 157篇 |
2019年 | 265篇 |
2018年 | 255篇 |
2017年 | 203篇 |
2016年 | 192篇 |
2015年 | 211篇 |
2014年 | 321篇 |
2013年 | 424篇 |
2012年 | 614篇 |
2011年 | 607篇 |
2010年 | 279篇 |
2009年 | 296篇 |
2008年 | 442篇 |
2007年 | 480篇 |
2006年 | 483篇 |
2005年 | 455篇 |
2004年 | 389篇 |
2003年 | 340篇 |
2002年 | 270篇 |
2001年 | 117篇 |
2000年 | 117篇 |
1999年 | 93篇 |
1998年 | 86篇 |
1997年 | 90篇 |
1996年 | 66篇 |
1995年 | 66篇 |
1994年 | 51篇 |
1993年 | 54篇 |
1992年 | 84篇 |
1991年 | 60篇 |
1990年 | 67篇 |
1989年 | 74篇 |
1988年 | 60篇 |
1987年 | 59篇 |
1986年 | 59篇 |
1985年 | 47篇 |
1984年 | 43篇 |
1983年 | 43篇 |
1982年 | 39篇 |
1981年 | 35篇 |
1979年 | 46篇 |
1978年 | 35篇 |
1977年 | 49篇 |
1976年 | 40篇 |
1975年 | 36篇 |
1972年 | 37篇 |
1970年 | 34篇 |
排序方式: 共有9060条查询结果,搜索用时 15 毫秒
101.
102.
几种中西药抗人实验模拟运动病效果观察 总被引:1,自引:0,他引:1
目的 :选用中药“治晕灵”的主要成分生姜、明天麻等六味草药煎成汤剂、或半量汤剂配西药脑益嗪、山莨菪碱各1 4临床常用量配成复方中西药制剂 ,与目前常用抗晕药晕海宁等中、西药的药效进行比较 ,看中药制剂或中西药复方制剂是否具有较好的抗运动病效果。方法 :选 7名敏感被试者 (女性 ,19~ 2 1岁 ) ,用旋转刺激诱发运动病至出现恶心。按拉丁方设计 ,与安慰剂 (淀粉 10 0mg)及晕海宁 (5 0mg)进行对比 ,分别观察了生姜合剂 (30ml)、晕可平 (30ml)、山莨菪碱 (10mg)、脑益嗪 (2 5mg)及上述复方中西药制剂口服后的运动病耐力。结果 :与安慰剂比较 ,晕海宁、山莨菪碱、脑益嗪、晕可平、生姜合剂、复方中西药制剂分别使运动病耐力提高 5 .4%、7.5 %、5 .9%、7.4%、32 .3 %、2 0 .4% ;生姜合剂效果较优 ,除口服时有辛辣味外 ,无明显的副作用。复方中西药制剂各成分未显示协同作用 ,而只是简单的作用相加。结论 :生姜合剂具有较好的抗运动病作用 相似文献
103.
Non-invasive detection of fecal protein kinase C betaII and zeta messenger RNA: putative biomarkers for colon cancer 总被引:2,自引:0,他引:2
Davidson LA; Aymond CM; Jiang YH; Turner ND; Lupton JR; Chapkin RS 《Carcinogenesis》1998,19(2):253-257
We have developed a non-invasive method utilizing feces, containing
sloughed colonocytes, as a sensitive technique for detecting diagnostic
colonic biomarkers. In this study, we used the rat colon carcinogenesis
model to determine if changes in fecal protein kinase C (PKC) expression
have predictive value in monitoring the neoplastic process. Weanling rats
were injected with saline or azoxymethane (AOM) and 36 weeks later fecal
samples and mucosa were collected, poly A+ RNA isolated, and quantitative
RT-PCR performed using primers to PKC betaII and zeta. Fecal PKC betaII and
zeta mRNA levels were altered by the presence of a tumor, with
tumor-bearing animals having a 3-fold higher (P < 0.05) PKC betaII
expression as compared with animals without tumors. In addition,
AOM-injection increased mucosal PKC betaII mRNA expression compared with
saline controls. No effect of tumor incidence on mucosal PKC betaII
expression was observed. In contrast, fecal PKC zeta expression was
2.5-fold lower (P < 0.05) in animals injected with azoxymethane versus
saline. Since tumor incidence exerts a reciprocal effect on fecal PKC
betaII and zeta mRNA expression, data were also expressed as the ratio
between PKC betaII and zeta. The isozyme ratio was strongly related to
tumor incidence, i.e. ratio for animals with tumors was 2.18 +/- 1.25,
animals without tumors was 0.50 +/- 0.16, P = 0.025. We demonstrate that
the expression of fecal PKC betaII and zeta may serve as a noninvasive
marker for development of colon tumors. A sensitive technique for the
detection of colon cancer is of importance since early diagnosis can
substantially reduce mortality.
相似文献
104.
Ronny A. Bell PhD MS ; Sara A. Quandt PhD ; Thomas A. Arcury PhD ; Beverly M. Snively PhD ; Jeanette M. Stafford MS ; Shannon L. Smith MA ; Anne H. Skelly PhD RN 《The Journal of rural health》2005,21(3):198-205
PURPOSE: Residents in rural communities in the United States, especially ethnic minority group members, have limited access to primary and specialty health care that is critical for diabetes management. This study examines primary and specialty medical care utilization among a rural, ethnically diverse, older adult population with diabetes. METHODS: Data were drawn from a cross-sectional face-to-face survey of randomly selected African American (n=220), Native American (n=181), and white (n=297) Medicare beneficiaries > or =65 years old with diabetes in 2 rural counties in central North Carolina. Participants were asked about utilization of a primary care doctor and of specialists (nutritionist, diabetes specialist, eye doctor, bladder specialist, kidney specialist, heart specialist, foot specialist) in the past year. FINDINGS: Virtually all respondents (99.0%) reported having a primary care doctor and seeing that doctor in the past year. About 42% reported seeing a doctor for diabetes-related care. On average, participants reported seeing 2 specialists in the past year, and 54% reported i seeing >1 specialist. Few reported seeing a diabetes specialist (5.7%), nutritionist (10.9%), or kidney specialist (17.5%). African Americans were more likely than others to report seeing a foot specialist (P < .01), while men were more likely than women to have seen bladder specialist (P = .02), kidney specialist (P = .001), and heart specialist (P = .004), after adjusting for potential confounders. Predictors of the number of specialists seen include gender, education, poverty status, diabetes medication use, and self-rated health. CONCLUSIONS: These data indicate low utilization of specialty diabetes care providers across ethnic groups and reflect the importance of primary care providers in diabetes care in rural areas. 相似文献
105.
106.
107.
An acquired G-CSF receptor mutation results in increased proliferation of CMML cells from a patient with severe congenital neutropenia. 总被引:1,自引:0,他引:1
M Germeshausen H Schulze C Kratz L Wilkens R Repp K Shannon K Welte M Ballmaier 《Leukemia》2005,19(4):611-617
Severe congenital neutropenia (CN) is characterized by a maturation arrest of myelopoiesis at the promyelocyte stage. Treatment with pharmacological doses of recombinant human granulocyte colony-stimulating factor (rh-G-CSF) stimulates neutrophil production and decreases the risk of major infectious complications. However, approximately 15% of CN patients develop myeloid malignancies that have been associated with somatic mutations in the G-CSF receptor (G-CSFR) and RAS genes as well as with acquired monosomy 7. We report a CN patient with chronic myelomonocytic leukemia (CMML) who never received rh-G-CSF. Molecular analysis demonstrated a somatic G-CSFR mutation (C2390T), which led to expression of a truncated G-CSFR protein in the CMML. Normal G-CSFR expression was unexpectedly absent in primary and cultured CMML. In addition, CMML cells showed monosomy 7 and an oncogenic NRAS mutation. In vitro culture revealed a G-CSF-dependent proliferation of CMML cells, which subsequently differentiated along the monocytic/macrophage lineage. Our results provide direct evidence for the in vivo expression of a truncated G-CSFR in leukemic cells, which emerged in the absence of rh-G-CSF treatment and transduces proliferative signals. 相似文献
108.
Elizabeth Tan-Chiu Greg Yothers Edward Romond Charles E Geyer Michael Ewer Deborah Keefe Richard P Shannon Sandra M Swain Ann Brown Louis Fehrenbacher Victor G Vogel Thomas E Seay Priya Rastogi Eleftherios P Mamounas Norman Wolmark John Bryant 《Journal of clinical oncology》2005,23(31):7811-7819
PURPOSE: Trastuzumab is effective in treating human epidermal growth factor receptor 2 (HER2) -positive breast cancer, but it increases frequency of cardiac dysfunction (CD) when used with or after anthracyclines. PATIENTS AND METHODS: National Surgical Adjuvant Breast and Bowel Project trial B-31 compared doxorubicin and cyclophosphamide (AC) followed by paclitaxel with AC followed by paclitaxel plus 52 weeks of trastuzumab beginning concurrently with paclitaxel in patients with node-positive, HER2-positive breast cancer. Initiation of trastuzumab required normal post-AC left ventricular ejection fraction (LVEF) on multiple-gated acquisition scan. If symptoms suggestive of congestive heart failure (CHF) developed, source documents were blindly reviewed by an independent panel of cardiologists to determine whether criteria were met for a cardiac event (CE), which was defined as New York Heart Association class III or IV CHF or possible/probable cardiac death. Frequencies of CEs were compared between arms. RESULTS: Among patients with normal post-AC LVEF who began post-AC treatment, five of 814 control patients subsequently had confirmed CEs (four CHFs and one cardiac death) compared with 31 of 850 trastuzumab-treated patients (31 CHFs and no cardiac deaths). The difference in cumulative incidence at 3 years was 3.3% (4.1% for trastuzumab-treated patients minus 0.8% for control patients; 95% CI, 1.7% to 4.9%). Twenty-seven of the 31 patients in the trastuzumab arm have been followed for > or = 6 months after diagnosis of a CE; 26 were asymptomatic at last assessment, and 18 remained on cardiac medication. CHFs were more frequent in older patients and patients with marginal post-AC LVEF. Fourteen percent of patients discontinued trastuzumab because of asymptomatic decreases in LVEF; 4% discontinued trastuzumab because of symptomatic cardiotoxicity. CONCLUSION: Administering trastuzumab with paclitaxel after AC increases incidence of CHF and lesser CD. Potential cardiotoxicity should be carefully considered when discussing benefits and risks of this therapy. 相似文献
109.
110.